IPO ChampIPO Insights
IPO Champ LogoIPO Champ Logo

IPOs

IPO Calendar
GMP Tracker
Subscription Status
Allotment Status
Stock Broker
  • Follow us on Instagram
  • Follow us on Facebook
  • Follow us on Threads
  • Follow us on YouTube
  • Follow us on Telegram
  • Follow us on WhatsApp
HomeIPOSymbiotec Pharmalab

About Symbiotec Pharmalab

Incorporated in 2002, Symbiotec Pharmalab Ltd. is a biopharmaceutical and bio technological company whose operations include development and manufacture of active pharmaceutical ingredients, nutritional ingredients and specialized products for domestic and international markets. The firm focuses on research-based manufacturing, quality and sustainability. It provides ingredients that contribute towards growth in pharmaceutical, nutraceutical and wellness industries. Having over three decades of industry experience, the firm has grown from a laboratory-scale manufacturer of steroidal-hormone APIs in 1995 to an industrial scale backward-integration platform having approvals from the United States Food and Drug Administration (US FDA), European Union Good Manufacturing Practices (EU-GMP), Ministry of Food and Drug Safety, Korea among others. By June 30, 2025, the firm had two industrial-scale API manufacturing plants with a maximum capacity of 584.67 metric tonnes (MT) of chemical synthesis and 300 kilolitres of fermentation capacity.

Checklist Quality Analysis

Revenue Growth

Live IPOs

National Stock Exchange of India logo

National Stock Exchange of India

Mainboard
Open  Close17th Sep 2026 - 21st Sep 2026
Issue Size22561.57 Cr
Min. Qty8 Shares
Issue Price₹ 1700.00
Live IPO
Antala Industries logo

Antala Industries

SME
Open  Close29th Oct 2026 - 5th Nov 2026
Issue Size22.98 Cr
Min. Qty2000 Shares
Issue Price₹ 62.00
Live IPO
Companies NameOpen - CloseIssue SizeMin. QtyIssue PriceApply
National Stock Exchange of India logo

National Stock Exchange of India

Mainboard
17th Sep 2026 - 21st Sep 202622561.57 Cr8 Shares₹ 1700.00
Antala Industries logo

Antala Industries

SME
29th Oct 2026 - 5th Nov 202622.98 Cr2000 Shares₹ 62.00
See All Live IPOs
IPO Champ LogoIPO Champ Logo

IPO Champ helps investors track upcoming, live and past IPOs in one place with GMP, subscription, allotment status and listing performance insights.

Tools

IPO CalendarGMP TrackerSubscription StatusAllotment Status

IPOs

All IPOsLive IPOsUpcoming IPOsClosed IPOsListed IPOs

Resources

NewseBooks

Company

HomeAbout UsPrivacy PolicyTerms of Service

About IPO Champ

IPO Champ is built for investors who want a clear view of every IPO opportunity in one place. From upcoming issues to live subscription data, allotment updates and listing performance, we bring together the key details you need to track the primary market.

Our tools are designed to be simple, fast and investor-friendly so you can focus on evaluating businesses instead of opening multiple tabs and websites for basic information.

Details of client bank account
For any query / feedback / clarifications, email at
help@ipochamp.com.

Please read all offer documents and risk disclosures carefully before investing. IPO Champ does not provide investment advice and information on this site should not be treated as a recommendation to apply for any IPO.

© 2026 IPO Champ. All rights reserved.

Want to stay updated?Subscribe to our newsletter

Symbiotec Pharmalab

Symbiotec Pharmalab

Open Date

Aug 24, 2026

Close Date

Aug 27, 2026

listed

Min Investment

₹14,820

Lot Size

15 Shares

Issue Size

₹1757 Cr

Price Range

₹938 - ₹938

Listing Date

Sep 1, 2026

IPO Doc

RHP PDF

Company Valuation

Earning Expansion

The investment checklist helps you understand a company's financial health at a glance and identify quality investment opportunities easily.

₹185(+18.72%)GMP
18.72%Prediction Listing Gain

Grey Market Premium (GMP) Trend

Symbiotec Pharmalab IPO - Issue Objectives

The company plans to use ₹112.50 crore to repay or prepay its outstanding borrowings. Part of the IPO proceeds will be used for general corporate purposes and issue expenses

Repayment of borrowings

75%

General corporate purposes

25%

1

Repayment of borrowings

The company plans to use ₹112.50 crore to repay or prepay its outstanding borrowings.

75.00%
2

General corporate purposes

Part of the IPO proceeds will be used for general corporate purposes and issue expenses

25.00%

IPO Subscription Status

QIB
181.20x
NII
77.56x
Individual
13.65x
Total
75.06x

Times subscribed by category (bars capped at 10x for readability). Dashed line marks 1.0x (fully subscribed).

Financials of Symbiotec Pharmalab

In Cr.

About Strength & Risks

Why this IPO looks interesting

Key positives investors may want to consider before applying.

01

Global leadership in some APIs

The company holds global leadership positions in molecules such as Hydrocortisone, Testosterone and Methylprednisolone, with market shares of 80.1%, 76.4% and 76.0%, respectively, in FY26, representing over 50% market share of supply by volume in each of these molecules.

02

Long-lasting customer relationship

69.49% of revenue from operations at ₹604.01 crore in FY26 contributed by the customers having more than 7 years of relationship with the company. The company added 101 new distinct customers in FY26, 96 in FY25 and 89 in FY24.

03

Multi scaled, vertically integrated manufacturing platform

As of March 31, 2026, Symbiotec operated two industrial-scale API manufacturing facilities and had commissioned two additional manufacturing facilities, taking aggregate maximum chemical synthesis capacity to 584.67 MT, fermentation capacity to 700 KL and complex injectables capacity to 20 million vials. The company is among the few players in India possessing multi-scale fermentation capabilities capable of producing both high volume and low volume fermentation based products.

What investors should watch closely

Risk factors and possible pressure points around the offer.

01

High dependence on APIs

96.07% of revenue from operations in FY26 contributed by APIs business. The top 10 products were even more concentrated at 78.96% in FY26. Any fall in demand, pricing or production of a few major APIs can have a meaningful impact.

02

Customer concentration is high

Top 10 customers contributed ₹465.47 crore, or 57.59% of revenue from sale of products, in FY26, compared with ₹401.58 crore or 55.90% in FY25 and does not maintain long-term contractual arrangements with customers and largely relies on purchase orders.

03

Contact Details

Symbiotec Pharmalab

385/2, Pigdamber, Rau, Mhow, Indore, Madhya Pradesh, 453331

+917316676405
secretarial@symbiotec.com
http://www.symbiotec.com/

Symbiotec Pharmalab IPO - FAQs

Symbiotec Pharmalab IPO is a Mainboard IPO. The issue is priced at 938-₹988. The minimum order quantity is 15 Shares. The IPO opens on 24 Aug, and closes on 27 Aug. TBA is the registrar for the IPO. The shares are proposed to be listed on BSE, NSE.

IPO Timeline

  • Pre Apply2026-08-21
  • Bidding Starts2026-08-24
  • Bidding Ends2026-08-27
  • Allotment Finalisation2026-08-28
  • Release of Funds2026-08-31
  • Demat Transfer2026-08-31
  • Listing2026-09-01
04

Continuous investment in R&D

As of 31 March 2026, Symbiotec had three dedicated R&D centers and R&D activities were organised across organic chemistry, biotechnology and complex injectables platforms. R&D expenditure was ₹29.70 crore, or 3.42% of revenue, in FY26, ₹31.14 crore, or 4.14% of revenue, in FY25 and ₹20.51 crore, or 2.86% of revenue, in FY24.

05

Strong financial metrics

Return on Capital Employed (ROCE) adjusted for capital expenditure not yet commissioned was at 30.43%, 27.71% and 24.59% in FY26, FY25 and FY24 respectively. Net cash flow from operating activities were ₹174.59 crore in FY26, ₹47.26 crore in FY25 and ₹187.50 crore in FY24.

Regulatory risk with recent US FDA observations

In FY26, the company underwent 3 quality audits by regulatory authorities and 21 customer audits. The Pithampur Facility was inspected by the US FDA on August 14, 2026, and the inspection resulted in four observations, which the company has to respond to within 15 working days.

04

All manufacturing is concentrated in Madhya Pradesh

As of March 31, 2026, the company's Rau, Pithampur, Ujjain and Mhow facilities were all located in MP and also operates three dedicated R&D centres there. Any natural disaster in the region could affect multiple facilities.

05

The US market has become a bigger exposure

Revenue from operations from the US has increased from 4.02% in FY25 to 13.12% in FY26. Although the generic pharmaceuticals and related critical healthcare supply chains are excluded from the current US tariff framework, future tariffs or other trade restrictions could increase costs and reduce price competitiveness.

06

Raw-material dependence on China

The company imported raw materials equal to 26.32% of total expenses. Of this, imports from China alone were 23.88% of total expenses. In FY25, China accounted for 16.82% of total expenses, while in FY24 it was as high as 52.79% of total expenses. This exposes Symbiotec to geopolitical tensions, trade restrictions, tariffs, currency movements and supply-chain disruptions involving China.